Tuesday, 23 August 2016

Side-Branch Intraductal of the Pancreas: Enucleation or Standard Pancreatic Resection: Systematic Review with Meta-Analysis

Side-branch intraductal papillary mucinous neoplasms (side-branch IPMN) of the pancreas have a low malignant potential. The conventional treatment for this lesion, according to location, if there are signs of possible malignancy, has been pancreaticoduodenectomy (PD), total pancreatectomy (P), central pancreatectomy (CP) or distal pancreatectomy (DP).

Intraductal of the Pancreas
Despite advances reported in recent years, standard pancreatectomies still carry a significant postoperative mortality ranging from 1 % to 4 %. These interventions are also associated with high postoperative morbidity and long-term disorders such as diabetes [4] and exocrine insufficiency. Less invasive surgery, including enucleation (EN) and resection of ucinate process (RUP), has been introduced for management of benign IPMN to preserve pancreatic function postoperatively and decrease postoperative mortality and morbidity.


However, recommendations and reports of postoperative complications and clinical outcomes following these procedures have been limited. The debate between PR and EN is still a challenge for surgeons. At our knowledge, this is the first meta-analysis to compare EN to PR for the treatment of side-branch IPMN.This systematic review aimed to determine whether the EN is associated or not with a higher risk of mortality and morbidity compared to PR techniques for side-branch IPMN of the pancreas.


No comments:

Post a Comment